Creative Biolabs has launched an integrated OMV & exosome-boosted CAR-T development platform, a next-generation vesicle-engineering approach designed to investigate strategies for overcoming barriers to CAR-T activity in solid-tumor models. The announcement matters because CAR-T therapy, while transformative in blood cancers, has struggled against solid tumors due to poor T-cell infiltration through dense stroma, an immunosuppressive tumor microenvironment that drives metabolic exhaustion, and safety concerns such as cytokine release syndrome, along with antigen heterogeneity and escape.
The new platform combines two complementary nanoscale vesicle technologies—bacterial outer membrane vesicles (OMVs) and mammalian-derived exosomes—into a unified, customizable pipeline. Each vesicle type targets a distinct bottleneck, allowing researchers to evaluate complementary effects across multiple barriers in parallel. A senior scientist at Creative Biolabs said the field has accepted that solid tumors require a fundamentally different approach, and the dual-mechanism toolkit enables researchers to investigate barriers from stroma penetration to metabolic persistence.
The OMV engineering arm functionally remodels the tumor microenvironment to promote CAR-T infiltration. Engineered OMVs can carry immunomodulatory or delivery payloads for investigating microenvironment remodeling. A standout innovation is the BROAD-CAR system, in which OMVs transiently program tumor cells in vivo to display synthetic antigens recognized by a universal CAR-T construct—a preclinical strategy for evaluating antigen redirection across heterogeneous tumor models. OMV surface engineering with targeting ligands guides CAR-T homing precision, while detoxified LPS strains require characterization of immunostimulatory activity and endotoxin-related safety, a critical differentiator from synthetic liposome carriers that lack intrinsic immune-activating capacity.
The exosome engineering arm provides a biocompatible support system to sustain CAR-T activity within the suppressive microenvironment. CAR-exosomes—exosomes directly displaying functional CARs on their surface—deliver antigen-specific tumor killing without live cell administration, with a safety profile that requires preclinical comparison with live-cell CAR-T approaches. Selected exosome systems are being investigated for transport across biological barriers, including the blood-brain barrier, and can be engineered to carry cytokines, checkpoint inhibitors, and survival signals intended to modulate CAR-T exhaustion and persistence.
A third service line equips both vesicle types with customized therapeutic payloads. Small molecules, nucleic acids such as mRNA, siRNA, and miRNA, and proteins can be co-encapsulated within a single vesicle for multimodal synergy. Metabolic microenvironment remodeling formulations alleviate iron-mediated oxidative stress, while vesicle-mediated checkpoint blockade enables localized, sustained PD-1/PD-L1 inhibition directly at tumor sites—maximizing activation while minimizing systemic toxicity.
For research teams selecting a vesicle-engineering partner, the company outlines three practical criteria: dual-modality integration to address stroma remodeling and persistence support simultaneously, verified LPS detoxification data to avoid endotoxin risk that can confound preclinical safety models, and cargo co-loading capacity to package small molecules, nucleic acids, and proteins within a single vesicle for combination strategies targeting multiple microenvironment pathways.
The platform also offers antigen-independent targeting via synthetic marker installation on cancer cells, cell-free CAR-exosome options for preclinical repeat-dosing and formulation studies, and project-specific ex vivo workflows designed to preserve favorable T-cell phenotypes. Full technical validation includes NTA sizing, high-resolution imaging, and pharmacokinetic profiling. The integrated OMV & exosome-boosted CAR-T development platform represents a shift toward dual-vesicle strategies that could accelerate preclinical evaluation of solid-tumor immunotherapies.
